BIO-FD&C CO. LTD

As of June 30, 2026, BIO-FD&C CO. LTD carries a market capitalization of 73.35B, placing it among publicly traded companies globally. Its enterprise value stands at 18.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BIO-FD&C CO. LTD's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, BIO-FD&C CO. LTD has 8.53M shares outstanding.

As of June 30, 2026, BIO-FD&C CO. LTD trades at a trailing price-to-earnings ratio of 11.45. The price-to-sales ratio is 3.75, and the price-to-book ratio stands at 1.01.

As of June 30, 2026, BIO-FD&C CO. LTD trades at an EV/EBITDA multiple of 2.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BIO-FD&C CO. LTD trades at an EV/FCF ratio of 3.18, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 18.10B versus a market cap of 73.35B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BIO-FD&C CO. LTD maintains a current ratio of 19.09, meaning it holds 19.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.26, indicating conservative leverage, while an interest coverage ratio of 370.55 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BIO-FD&C CO. LTD posted a return on equity (ROE) of 9.19, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.98 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.78, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.18, useful for judging operating efficiency across full business cycles. The company generates approximately 252.05M in revenue per employee across its workforce of 77.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.96 indicates how many times BIO-FD&C CO. LTD sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BIO-FD&C CO. LTD recorded 1.50B in income tax expense. That works out to an effective tax rate of 18.98, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.91B, leaving 6.41B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, BIO-FD&C CO. LTD's stock has declined approximately 42.26% over the past 52 weeks. The 50-day moving average sits at 9,220.60, while the 200-day moving average is 11,616.45.

Over the twelve months ended June 30, 2026, BIO-FD&C CO. LTD generated 19.53B in revenue and converted that into 6.41B in net income, yielding earnings per share of 751.14. EBITDA reached 7.51B, while operating income came in at 6.10B.

As of June 30, 2026, BIO-FD&C CO. LTD holds 55.44B in cash and equivalents against 187.52M in total debt, resulting in a net debt position of -12.44B. Total book value stands at 72.93B, with working capital of 58.25B providing operational flexibility.

BIO-FD&C CO. LTD produced 6.44B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -766.37M in capital expenditures, free cash flow totaled 5.67B - equivalent to 664.86 per share.

Over the twelve months ended June 30, 2026, BIO-FD&C CO. LTD posted a gross margin of 66.29, reflecting its pricing power and cost economics. The operating margin of 31.22 and net profit margin of 32.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 7.73, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BIO-FD&C CO. LTD shareholders.

As of June 30, 2026, BIO-FD&C CO. LTD has an Altman Z-Score of 14.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.